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Transformation  of  lymphoid  progenitor  cells 
leads to the development of acute lymphoblas-
tic leukemia (ALL). The majority of ALL cases 
involve transformation of B lineage cells, with 
only a small percentage of cases resulting from 
T cell transformation. ALL is thought to be 
caused by genetic lesions in genes critical for 
proliferation,  differentiation,  and  survival  of 
progenitor cells (Pui et al., 2008). These lesions 
include  chromosomal  translocations  such  as 
BCR-ABL or E2A-PBX. BCR-ABL represents 
a fusion gene from a chromosomal translocation 
called the Philadelphia Chromosome and often 
results in a poor outcome (Milone and Enrico, 
2009; Fielding, 2010). The BCR-ABL translo-
cation results in the activation of signal transducer 
and activator of transcription (STAT5), a tran-
scription factor that is important for B cell de-
velopment (Carlesso et al., 1996; Ilaria and Van 
Etten, 1996). Recent work by Mullighan et al. 
(2007) has provided new insight into genetic 
lesions that may be involved in ALL and fur-
ther illustrated the importance of several addi-
tional genes known to be critical in early stages of 
B cell development and differentiation. In that 
study, they found that 40% of the genetic alter-
ations identified were in principal regulators of   
B cell development including early B cell factor 1 
(EBF1) and paired box gene 5 (PAX5) with PAX5 
modifications accounting for >30% of the cases. 
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As STAT5 is critical for the differentiation, proliferation, and survival of progenitor B cells, 
this transcription factor may play a role in acute lymphoblastic leukemia (ALL). Here,  
we show increased expression of activated signal transducer and activator of transcription 5 
(STAT5), which is correlated with poor prognosis, in ALL patient cells. Mutations in EBF1 
and PAX5, genes critical for B cell development have also been identified in human ALL.  
To determine whether mutations in Ebf1 or Pax5 synergize with STAT5 activation to induce 
ALL, we crossed mice expressing a constitutively active form of STAT5 (Stat5b-CA) with 
mice heterozygous for Ebf1 or Pax5. Haploinsufficiency of either Pax5 or Ebf1 synergized 
with Stat5b-CA to rapidly induce ALL in 100% of the mice. The leukemic cells displayed 
reduced expression of both Pax5 and Ebf1, but this had little effect on most EBF1 or PAX5 
target genes. Only a subset of target genes was deregulated; this subset included a large 
percentage of potential tumor suppressor genes and oncogenes. Further, most of these 
genes appear to be jointly regulated by both EBF1 and PAX5. Our findings suggest a model 
whereby small perturbations in a self-reinforcing network of transcription factors critical 
for B cell development, specifically PAX5 and EBF1, cooperate with STAT5 activation to 
initiate ALL.
© 2011 Heltemes-Harris et al.  This article is distributed under the terms of an 
Attribution–Noncommercial–Share  Alike–No  Mirror  Sites  license  for  the  first   
six months after the publication date (see http://www.rupress.org/terms). After   
six months it is available under a Creative Commons License (Attribution– 
Noncommercial–Share Alike 3.0 Unported license, as described at http://creative-
commons.org/licenses/by-nc-sa/3.0/).
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arrested at the late pro–B cell stage in the bone marrow. 
Moreover, Pax5/ pro–B cells are not committed to the   
B cell lineage and are able to convert to other hematopoietic 
cell types such as T cells or myeloid cells (Nutt et al., 1999). 
EBF1 has been shown to bind to the Pax5 promoter and   
induce Pax5 expression (Cobaleda et al., 2007). Interestingly, 
although EBF1 is expressed earlier than PAX5, PAX5 binds 
the Ebf1 promoter and is required to maintain normal levels 
of Ebf1 expression (Cobaleda et al., 2007; Roessler et al., 
2007). Thus, PAX5 and EBF1 act as part of a self-reinforcing 
network that induces genes critical for B cell differentia-
tion and represses genes involved in differentiation of other 
cell lineages.
Though a correlation has been identified between tran-
scription factors critical for early B cell development and 
ALL, little is known regarding the mechanism by which this 
promotes transformation. Moreover, data supporting these 
mutations as drivers in the transformation process rather than 
just passengers are also absent. In this paper, we demonstrate 
that elevated levels of STAT5 phosphorylation (phospho-
STAT5) are found in certain subgroups of human ALL, and 
these elevated levels of pSTAT5 correlate with poor disease 
outcome after treatment. Using Stat5b-CA mice, we demon-
strate that STAT5 synergizes with haploinsufficiency of   
either Ebf1 or Pax5 to rapidly induce progenitor B-ALL. 
Stat5b-CA x Ebf1+/ and Stat5b-CA x Pax5+/ leukemias 
show reduced expression of both Ebf1 and Pax5 with effects 
on a subset of EBF1 and PAX5 responsive genes. The subset 
of EBF1/PAX5-responsive genes includes potential tumor 
suppressor genes, oncogenes, and B cell growth factors. 
Therefore, changes in Ebf1 and Pax5 expression, such as 
those caused by haploinsufficiency, can result in changes in 
gene expression leading to induction of oncogenes and re-
pression of tumor suppressor genes involved in ALL. Further, 
we demonstrate that the development of leukemia requires 
continued expression of IL-7 or thymic stromal lymphopoi-
etin (TSLP) through use of a mouse model and a newly cre-
ated  ALL  mouse  cell  line.  Collectively,  our  data  support   
a model in which multiple small defects in a network of fac-
tors that govern B cell development lead to a loss of tumor 
suppressor function and aberrant induction of oncogenes 
that cooperate with STAT5 activation to initiate progenitor 
B cell leukemia.
RESULTS
Increased STAT5 activation in adult human ALL patients 
correlates with poor outcome
To determine whether STAT5 plays a critical role in human 
ALL, we examined ALL patient samples using a newly de-
scribed reverse phase proteomics approach (Kornblau et al., 
2009). Consistent with previous microarray studies (Yeoh   
et al., 2002), we found no increase in total STAT5 protein in 
human ALL (Table S1). In contrast, some of the ALL patient 
samples (n = 129; Table S1) exhibited clearly elevated levels 
of phosphorylated STAT5 (phospho-STAT5; Fig. 1 A). The 
level of phospho-STAT5 varied significantly between ALL 
This indicates that disruption of genes involved in critical stages 
of B cell development may lead to B cell leukemia.
STAT5 plays a critical role in both B and T cell develop-
ment and is encoded by two closely linked genes, Stat5a and 
Stat5b, which give rise to functionally redundant proteins. 
Conditional STAT5 deletion strategies found reduced num-
bers of common lymphoid progenitors and pre/pro–B cells 
in Stat5/ mice, whereas pro–B cells and later stages of   
B cell differentiation were absent (Yao et al., 2006; unpub-
lished data). Thus, STAT5 plays a critical role in early B cell 
differentiation. We previously generated mice expressing a 
constitutively active form of STAT5 (Stat5b-CA) throughout 
B and T cell development (Burchill et al., 2003). These 
mice exhibit a marked expansion of pro–B and pre–B cells 
(5-fold increase). Despite this increase in B cell progenitors, 
the number of mature B cells in Stat5b-CA mice is not sig-
nificantly different from that observed in wild–type littermate 
controls. However, we found that our Stat5b-CA transgenic 
mice develop a disease resembling human ALL, although 
with  low  penetrance  (1  to  2%;  Burchill  et  al.,  2003;   
Nakayama et al., 2009). Previous research has suggested that 
STAT5 may play an important role in cancer, including ALL. 
For example, work by Weber-Nordt et al. (1996) found con-
stitutive STAT5 activation in the majority of ALL samples 
they examined, the caveat being that only 3 live and 12 fixed 
samples were examined in this study. Additional studies have 
shown that STAT5 is activated by several oncogenic proteins 
including BCR-ABL (Xie et al., 2001; Buettner et al., 2002). 
This was accomplished by engineering bone marrow–derived 
cells to express BCR-ABL or TEL-JAK2 fusion proteins that 
initiate leukemia upon transfer into histocompatible recipient 
mice. However, if the engineered bone marrow cells also lack 
the Stat5a and Stat5b genes, leukemia does not result (Schwaller 
et al., 2000; Hoelbl et al., 2006). These findings suggest a pos-
sible role for STAT5 activation in initiating ALL.
Transcriptional regulation plays a critical role in B cell 
differentiation with expression of distinct sets of genes at dis-
crete stages resulting in the initiation of lineage differentia-
tion.  Two  genes  crucial  for  initiating  and  maintaining   
B lineage specificity are Ebf1 and Pax5 (Hagman and Lukin, 
2006; Nutt and Kee, 2007). Loss of the Ebf1 gene in mice re-
vealed a block in B cell differentiation before the develop-
ment of prepro–B cells (Lin and Grosschedl, 1995b). In 
addition, mice heterozygous for Ebf1 show a 50% reduction 
in mature B cells but normal levels of pro–B cells (Lin and 
Grosschedl, 1995b). EBF1 is clearly involved in the expres-
sion of many B cell–specific genes, including the transcrip-
tion factor PAX5 (Månsson et al., 2004; Nutt and Kee, 2007). 
More recent studies have documented that EBF1 also re-
presses several genes that interfere with B cell development 
(Pongubala et al., 2008; Treiber et al., 2010). As a multifunc-
tional transcriptional regulator, PAX5 represses expression of 
genes involved in commitment to other lineages while acti-
vating B cell–specific genes such as Cd19 and Blnk (Nutt   
et al., 1999; Cobaleda et al., 2007; Schebesta et al., 2007).   
In the absence of PAX5 expression, B cell development is   JEM Vol. 208, No. 6  1137
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Ebf1 and Pax5 heterozygosity cooperate with STAT5 
activation to initiate highly penetrant ALL
Recent analyses of ALL samples have identified a large num-
ber of mutations in transcription factors required for B cell 
development, including PAX5 and EBF1 (Mullighan et al., 
2007). As STAT5 has been implicated in governing EBF1 
and PAX5 expression and plays a possible role in ALL, we 
were interested in studying what affect loss of EBF1 or PAX5 
would have on mice expressing an activated form of STAT5. 
We have previously described transgenic mice that express a 
constitutively active form of STAT5 (Stat5b-CA) and de-
velop a disease that mimics human ALL, albeit at very low 
penetrance (1 to 2%; Burchill et al., 2003; Nakayama et al., 
2009).  To  examine  potential  cooperativity  between  STAT5   
activation and defects in Ebf1 or Pax5 in initiating leukemia, 
we generated Stat5b-CA x Ebf1+/ and Stat5b-CA x Pax5+/ 
mice. Loss of both alleles of Pax5 in mature B cells has been 
shown to result in back differentiation and development of 
progenitor B cell leukemias with a median age of onset of   
9 mo (Cobaleda et al., 2007). However, Ebf1+/ and Pax5+/ 
mice never develop leukemia (Fig. 2 A; Urbánek et al., 1994; 
Lin and Grosschedl, 1995a). In contrast, loss of one allele of 
either Pax5 or Ebf1 in combination with constitutively active 
STAT5b resulted in rapid induction of leukemia with com-
plete penetrance (median onset 55 and 109 d, respectively; 
Fig. 2 A). Leukemic Stat5b-CA x Ebf1+/ or Stat5b-CA x 
Pax5+/ displayed grossly enlarged lymph nodes and spleen 
(Fig. 2 B). Further, leukemic cell infiltration was found in the 
spleen and lymph nodes as well as in bone marrow, blood, 
thymus, and liver (unpublished data). To determine the phe-
notype, cells from spleen, lymph node, and bone marrow 
were removed from wild-type and leukemic mice and stained 
for markers expressed throughout B cell development. The 
leukemic  cells  express  AA4.1,  IL-7R,  B220  (intermediate 
levels),  and  CD19  but  do  not  express  IgM,  pre–BCR,   
or IgD, indicating that they are progenitor B cells (Fig. 2 C 
and Fig. S1 A).
To determine if activation of STAT5b coupled with Ebf1 
or Pax5 heterozygosity is sufficient to induce ALL, we tested 
clonality by assessing VDJ rearrangements in leukemic cells. 
Although the resolution of our assay does not allow us to dis-
criminate between oligoclonal versus monoclonal leukemia, 
our analysis of VDJ rearrangements indicates that the leukemic 
cells are clearly not polyclonal (Fig. S1 B). Thus, leukemia 
initiates from either a single clone or a small number of clones 
in our model. This finding indicates that although STAT5   
activation and loss of one allele of Ebf1 or Pax5 is critical for 
transformation, additional mutations are also necessary.
Constitutive activation of STAT5 leads to increased num-
bers of pro–B and pre–B cells as well as CD8+ memory-like 
T cells and CD4+ regulatory T cells (Burchill et al., 2003).   
To rule out any cell-extrinsic effect of the environment in 
our Stat5b-CA transgenic model, leukemic cells were trans-
ferred intravenously into recipient mice. The transferred cells 
induced leukemia in 100% of the recipient mice (unpublished 
data). These experiments were initially done by injecting a 
cytogenetic subsets with the highest expression observed in 
BCR-ABL+ ALL (Fig. 1 A). Historically, the overall survival 
of BCR-ABL+ patients is quite poor, although the introduc-
tion of imatinib as a therapy has improved survival (Thomas 
et al., 2004). Intriguingly, we found that phospho-STAT5 
status before treatment with imatinib predicted the response 
to subsequent imatinib therapy, with higher levels of phos-
pho-STAT5, correlating with significantly poorer overall 
survival (Fig. 1 B). These results demonstrate that a signifi-
cant fraction of patients with ALL exhibit elevated levels of 
activated STAT5 and that the degree of STAT5 activation 
correlates with outcome in at least one subset of ALL.
Figure 1.  Increased STAT5 activation in adult human ALL patients 
correlate with poor prognosis. (A) Shown are the relative levels of 
phospho-STAT5 (tyrosine 694/699) in cells from indicated human ALL 
cytogenetic subtypes (hyperdiploid, hypodiploid, immature B cell [IM], 
miscellaneous [Misc], no analyzable metaphases [NAM], Bcr-Abl [Ph+], 
pseudodiploid, diploid, t[11;14], t[4;11], t[8,14], t[8;22], and t[11;19]). Solid 
black bars represent the median and solid boxes represent the 25–75% 
range; dashed lines give ± 2 SD and open circles represent outliers. The 
number of samples for each subset is listed above the plot. (B) Bcr-Abl 
patients were separated into two equal groups representing higher (red 
line, n = 5) and lower (blue line, n = 6) levels of phospho-STAT5 (pSTAT5). 
All of these patients were subsequently treated with combination chemo-
therapy, including a tyrosine kinase inhibitor imatinib, and overall survival 
was determined. (P = 0.03, Log Rank [Mantle-Cox] test).1138 Roles of Ebf1, Pax5, and STAT5 in ALL | Heltemes-Harris et al.
bone marrow were analyzed and com-
pared with wild-type pro–B cells and 
preinjection leukemic cells. We found 
that the cells retained their preinjec-
tion phenotype including expression 
of AA4.1,  B220,  CD19,  and  IL-7R 
(Fig. 2 D). This suggests that genetic 
alterations necessary for leukemic induction are intrinsic to 
the transformed cell.
A block in B cell development influences, but does  
not recapitulate, leukemia development seen  
in Stat5b-CA x Ebf1+/ and Stat5b-CA x Pax5+/ mice
We next wanted to determine if leukemic transformation was 
caused by a block in early B cell differentiation. As both EBF1 
and PAX5 are critical for B cell development and homozy-
gous loss of either results in a complete disruption of B cell 
development, we generated Stat5b-CA x Rag2/ mice. The 
Rag2 mutation blocks development beyond the late pro–B cell 
stage similar to Pax5 mutation, but later than the Ebf1 muta-
tion. Approximately half of the Stat5b-CA x Rag2/ mice came 
down with progenitor B cell leukemia. However, the median 
age of tumor onset was significantly later in these mice (203 d) 
as compared with either Stat5b-CA x Ebf1+/ or Stat5b-CA x 
Pax5+/, and the overall frequency of leukemia was significantly 
reduced (P < 0.0001; Fig. 3 A). Both microarray and flow cyto-
metric  analysis  indicated  that  most  Stat5b-CA  x  Rag2/ 
large number of leukemic cells (5 × 106 cells), both by intra-
venous and intraperitoneal injection, into immunocompro-
mised  mice  containing  no  B, T,  or  NK  cells  (Rag2/  x 
Il2rg/). As this procedure induced rapid onset of leukemia 
(<2 wk; unpublished data), we next transferred the leukemia 
cells into unmanipulated C57BL/6 syngeneic hosts. Again,   
5 × 106 cells were injected, this time by intravenous injection. 
The mice again succumbed to disease rapidly. As the synge-
neic host did not reject the leukemia cells, we continued by 
titrating down to 1,000 leukemic cells per mouse, again trans-
ferring the cells intravenously. In all cases, the animals suc-
cumbed to disease in <30 d. In addition, we were able to 
serially transfer the leukemia cells from one mouse recipient 
to a new mouse recipient with a similar outcome. Onset of 
leukemia did not seem to be dependent on cell number, sug-
gesting that even fewer transferred cells would be sufficient to 
induce death from leukemia. All recipient mice were charac-
terized by enlarged lymph nodes and spleen with leukemic 
cell infiltration in other tissues including liver, thymus, and 
bone marrow. Cells recovered from spleen, lymph nodes, and 
Figure 2.  Ebf1 and Pax5 heterozygosity 
cooperates with STAT5 activation to initi-
ate highly penetrant ALL. (A) Kaplan-Meier 
survival analysis of mice of the indicated  
genotype. (B) Pictures of spleens and lymph 
nodes from leukemic Stat5b-CA x Ebf1+/ and 
Stat5b-CA x Pax5+/ tumor mice compared 
with a wild-type C57BL/6 control littermate 
(LMC) mouse. Tick marks represent millimeter 
measurement. (C) Flow cytometric analysis of 
lymph node cells from Stat5b-CA x Ebf1+/ 
and Stat5b-CA x Pax5+/ tumor mice. Repre-
sentative flow cytometric analysis of B220, 
AA4.1, IL-7R, pre–BCR, CD19, IgM, and IgD 
expression on lymph node cells is shown. 
Doublets were gated out and a lymphocyte 
gate was set based on side and forward scat-
ter properties. All gates shown are based on 
bone marrow isolated from LMC. In histogram 
plots, LMC is represented as shaded plot with 
line and the black line referred to as tumor 
represents cells isolated from the lymph 
nodes of indicated leukemic mouse. Each 
mouse designated in A was analyzed. (D) Flow 
cytometric analysis of Stat5b-CA x Pax5+/ 
leukemia cells before and after transfer (2–3 wk) 
into wild-type C57BL/6 recipients. At least 
three independent experiments were com-
pleted with at least one mouse per group per 
experiment.JEM Vol. 208, No. 6  1139
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examined  whether  enhancing  cell  survival  is  sufficient  to   
account for the affect of STAT5 on leukemia induction by 
crossing Ebf1+/ mice to mice expressing a Bcl-xl transgene 
(Fang et al., 1998). If the role of STAT5b-CA were to pro-
mote survival, then simply replacing activated STAT5 with 
BCL-XL should also induce leukemia in our model. Impor-
tantly, our Bcl-xl transgenic mice have an increase in pro–B cell 
numbers similar to that seen in our Stat5b-CA model. More-
over, it has previously been shown that crossing these Bcl-xl 
mice to c-Myc transgenic mice greatly accelerates the onset of 
ALL (Swanson et al., 2004). In contrast, we found that en-
forced Bcl-xl expression in Ebf1+/ mice did not lead to leu-
kemia (Fig. 3 C). Thus, STAT5 effects on survival may be 
necessary, but are clearly not sufficient to induce leukemia.
Increased  proliferation  could  also  account  for  the  in-
creased cellularity found in our leukemic mice. To determine 
if the leukemic cells were proliferating more rapidly than 
wild-type pro–B and pre–B cells, we injected mice displaying 
visible signs of leukemia with BrdU. In both Stat5b-CA x 
Ebf1+/  and  Stat5b-CA  x  Pax5+/ 
mice we found that the leukemic cells 
proliferate more rapidly than mature   
B cells but proliferate similarly to wild-
type cells at the same stage of B cell 
development (Fig. S3). Therefore, the 
development  of  leukemia  does  not   
appear to be caused by an effect of 
STAT5 on cell proliferation above and 
beyond  that  observed  in  wild-type 
progenitor B cells.
The IL-7R chain is required  
for induction and maintenance  
of leukemia
To further study the leukemic cells, we 
established a cell line from Stat5b-CA x 
Pax5+/ leukemic lymph node cells. 
leukemias resembled Stat5b-CA x Ebf1+/ and Stat5b-CA x 
Pax5+/ leukemias (Fig. 3 B; Fig. S2; and not depicted). Simi-
lar results were seen when crossing Stat5b-CA mice to MT/ 
mice, which also exhibit a complete block in B cell differen-
tiation caused by the absence of the immunoglobulin heavy 
chain gene (unpublished data). This finding suggests that al-
though inhibiting B cell differentiation is important, other 
effects also contribute to transformation.
Increased survival or proliferation does not recapitulate 
STAT5 effects on initiating leukemia
STAT5 is known to induce several genes involved in promot-
ing cell proliferation and survival. Recently, Malin et al. (2010) 
have suggested that the role of STAT5 in pro–B cells is to 
provide survival signals through the regulation of the anti-
apoptotic protein MCL1. Specifically, they demonstrated that 
overexpression of the prosurvival factor BCL2 largely rescued 
pro–B cell development in mice in which Stat5 had been de-
leted throughout B and T cell development. Therefore, we 
Figure 3.  Role of proliferation and sur-
vival in tumor induction. (A) Kaplan-Meier 
survival analysis of mice of the indicated geno-
types. (B) Flow cytometric analysis of lymph 
node cells from Stat5b-CA x Rag2/ tumor 
mice. Representative flow cytometric analysis 
of B220, AA4.1, IL-7R, pre–BCR, CD19, IgM, 
and IgD expression on lymph node cells is 
shown. In histogram plots, LMC is represented 
as shaded plot with line and the black line 
referred to as tumor represents cells isolated 
from the lymph nodes of indicated leukemic 
mouse. Doublets were gated out and a lym-
phocyte gate was set based on side and for-
ward scatter properties. All gates shown are 
based on bone marrow isolated from control 
C57BL/6 mice (LMC). Each mouse indicated in 
A was analyzed. (C) Kaplan-Meier survival 
analysis of mice of the indicated genotypes.1140 Roles of Ebf1, Pax5, and STAT5 in ALL | Heltemes-Harris et al.
restore B cell development to near normal levels (Goetz et al., 
2005). We crossed Stat5b-CA x Pax5+/ mice to IL-7r / mice 
to generate Stat5b-CA x Pax5+/ x IL-7r +/ or Stat5b-CA x 
Pax5+/ x IL-7r / mice. As seen in Fig. 4 B, mice lacking the 
IL-7r do not come down with ALL, whereas mice heterozygous 
for the IL-7r come down with leukemia similarly to Stat5b-CA x 
Pax5+/ mice. This suggests that signaling through the IL-7R 
plays a critical role in the induction of ALL.
Reduced expression of Ebf1 and Pax5 in both Stat5b-CA x 
Ebf1+/ and Stat5b-CA x Pax5+/ leukemias
As both EBF1 and PAX5 play a critical role in B cell devel-
opment, and we are using Ebf1 and Pax5 haploinsufficient 
mice, we set out to determine the expression levels of each   
of these transcription factors. We purified B220lowCD19+ 
IgMIgL cells from the bone marrow of control C57BL/6 
and Stat5b-CA mice and leukemic cells from the lymph nodes   
of Stat5b-CA x Pax5+/ and Stat5b-CA x Ebf1+/ leukemic 
mice. Expression was analyzed using quantitative real-time 
PCR (qRT-PCR). Consistent with our previous observa-
tion (Goetz et al., 2005) progenitor B cells from Stat5b-CA 
mice show increased expression of Pax5 relative to wild-type 
progenitor B cells (Goetz et al., 2005; Fig. 5 A). Furthermore, 
we also found increased expression of Ebf1 in Stat5b-CA pro-
genitor B cells (Fig. 5 A). In contrast, both the Stat5b-CA x 
Pax5+/ and Stat5b-CA x Ebf1+/ leukemic cells expressed 
reduced levels of Ebf1 and Pax5 when compared with wild-
type and Stat5b-CA progenitor B cells.
EBF1 and PAX5 are known to regulate each other’s expres-
sion. Therefore, we set out to determine whether Stat5b-CA x 
Ebf1+/ mice expressed reduced levels of PAX5 protein before 
leukemia onset. To address this issue, we made use of PAX5 
intracellular staining of cells isolated from the bone marrow of 
wild-type, preleukemic, and leukemic mice. Using progenitor 
B cells from wild-type mice as a control for normal levels of 
PAX5 expression, we found that PAX5 was expressed at nor-
mal to slightly higher than normal levels in Stat5b-CA, Stat5b-
CA  x  Ebf1+/  preleukemic,  and  Ebf1+/  mice  (Fig.  5  B).   
As seen in the PCR experiments assessing transcript level, the 
Stat5b-CA x Ebf1+/ leukemic cells also expressed reduced 
levels of PAX5 protein. This indicates that haploinsufficiency 
for Ebf1 does not result in reduced levels of PAX5 in non-
leukemic cells. Thus, independent mutations in Pax5 itself or 
factors that control its expression are required to reduce Pax5 
expression in Stat5b-CA x Ebf1+/ leukemia cells.
A subset of Ebf1- and Pax5-induced genes are deregulated 
in Stat5b-CA x Ebf1+/ and Stat5b-CA x Pax5+/ leukemias
Although both Ebf1 and Pax5 levels are reduced in Stat5b-CA x 
Ebf1+/ and Stat5b-CA x Pax5+/ leukemias, the reduction 
was quite modest (approximately twofold). Therefore, we 
were interested in determining if there were perturbations in 
known gene targets of either EBF1 or PAX5. To this end, we 
used RT-PCR and flow cytometry to analyze leukemic cells 
for expression of several known up-regulated gene targets   
including Cd79a, Blnk, and Cd19. We found that reduced 
Proliferation of this cell line in vitro was dependent on either 
IL-7 or TSLP (Fig. 4 A and Fig. S4); none of the other cyto-
kines tested, including SCF and FLT3L, could sustain prolif-
eration of this cell line (Fig. S4). Next, we titrated IL-7 and 
found that a relatively low dose (1 ng/ml) of IL-7 was all that 
was necessary for cell survival (Fig. 4 A). To address the issue of 
TSLP promoting leukemia survival, flow cytometric analysis 
of surface expression of TSLP receptor on preleukemic pro-
genitor B cells and leukemic lymph node cells was done.   
In these experiments, we found TSLP receptor expression   
at higher levels on leukemic cells than on wild-type cells 
(Fig. S4 B). To determine whether this cell line could cause 
leukemia  in  vivo,  we  transferred  106  cells  into  wild-type 
mice and monitored the mice for leukemia. The Stat5b-CA x 
Pax5+/ cell line was capable of inducing leukemia in wild-
type mice. Cells isolated from these new tumors maintained 
their preinjection phenotype and were found in the lymph 
nodes, spleen, and bone marrow of the recipient animals (un-
published data).
To  further  confirm  the  importance  of  the  IL-7R  in   
progenitor B-ALL, we made use of IL-7R knockout mice 
(IL-7r/), which are defective in both IL-7- and TSLP- 
dependent signaling. We have previously demonstrated that 
expression of our Stat5b-CA transgene in IL-7r/ mice can 
Figure 4.  Role of IL-7 in tumor induction. (A) Titration of IL-7 on 
Stat5b-CA x Pax5+/ cell line (SP1). Concentrations of IL-7 were 1, 5, and 
10 ng/ml. Cells were counted at each time point and graphed. Graph is 
representative of two independent experiments. (B) Kaplan-Meier survival 
analysis of Stat5b-CA x IL-7R+/ x Pax5+/ and Stat5b-CA x IL-7R/ x 
Pax5+/ mice.JEM Vol. 208, No. 6  1141
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induced  genes  we 
could  further  dem-
onstrate that the ma-
jority of these genes (64%) are also potential EBF1 targets, 
as previous studies have shown EBF1 binding to these same 
genes (Treiber et al., 2010). Thus, these data demonstrate that 
haploinsufficiency of Ebf1 in the presence of activated STAT5b 
results in reduced expression of a small subset of genes acti-
vated by EBF1 and PAX5.
Reduced expression of EBF1 and PAX5 results in derepression 
of genes that promote proliferation or survival
In addition to their role in activating genes required for B cell 
development, EBF1 and PAX5 have both been shown to 
play a key role in suppressing the expression of genes associated 
with other cell fates such as Notch1 or Tnsf11 (Delogu et al., 
2006; Pridans et al., 2008; Treiber et al., 2010). These factors 
also appear to restrain expression of genes involved in cell sur-
vival, such as Bcl2, or cell proliferation, such as c-Myc (Nutt   
et al., 1998). In examining expression of EBF1- and PAX5-
repressed genes, we found that the majority of these repressed 
genes were unaffected by reductions in EBF1 and PAX5 (60 
and 75%, respectively; Fig. 6 B; Table S3). However, a clear 
expression  of  Pax5  and  Ebf1  did  not  affect  expression  of 
Cd79a, Blnk, or Cd19 (Fig. 2 C and Fig. 5 C). To further in-
vestigate changes in gene expression, we performed microarray 
analysis on samples from wild-type and Stat5b-CA progenitor 
B  cells  and  Stat5b-CA  x  Ebf1+/  leukemic  B220+CD19+ 
lymph node cells. We then compared our results with previ-
ously published datasets of EBF1- and PAX5-activated genes 
(Schebesta et al., 2007; Pongubala et al., 2008; Pridans et al., 
2008; Treiber et al., 2010) and found that the majority of 
EBF1 and PAX5-induced genes (75.6 and 73.5%, respectively) 
were unaffected by twofold reductions in Ebf1 and Pax5  
expression (Fig. 6 A and Table S2). However, 25% of EBF1-
induced genes were down-regulated, suggesting that they were 
sensitive to small perturbations in Ebf1 expression (Table S3). 
These include several potential tumor suppressor genes in-
cluding Bcl7a, Cyfip2, and Rgs2 (Zani et al., 1996; Jackson   
et al., 2007; Schwäble et al., 2005; van Doorn et al., 2005). 
Likewise, 25% of PAX5-induced genes were also down-
regulated  in  Stat5b-CA  x  Ebf1+/  leukemias,  including   
potential tumor suppressor genes or genes involved in sup-
pressing cell proliferation such as Bach2, Btg1, Btg2, and Ucp2 
(Table  S3;  Rouault  et  al.,  1992,  1996;  Sasaki  et  al.,  2000;   
Lim, 2006; Baffy, 2010). Interestingly, in the case of PAX5- 
Figure 5.  Regulation of B cell develop-
mental genes. (A) Ebf1 and Pax5 expression 
in progenitor B cells from LMC and Stat5b-CA 
mice and B220+, CD19+ leukemic cells from 
lymph nodes of Stat5b-CA x Ebf1+/ and 
Stat5b-CA x Pax5+/ mice were measured by 
real-time RT-PCR. Blue bars represent expres-
sion of Ebf1 and red bars represent expression 
of Pax5. Each bar is representative of at least 
three mice from independent experiments. 
Error bars represent the SEM. (B) Intracellular 
flow cytometric analysis of PAX5 expression 
in B220Int bone marrow cells from Stat5b-CA 
nonleukemic mice, Ebf1+/ nonleukemic mice, 
Stat5b-CA x Ebf1+/ preleukemic mice, and 
lymph node cells from Stat5b-CA x Ebf1+/ 
leukemic mice. LMC B220 negative cells 
(PAX5) and LMC B220Int B cells (PAX5+) are 
controls. All gates shown are based on bone 
marrow isolated from control C57BL/6 mice. 
Doublets were gated out and a lymphocyte 
gate was set based on side and forward scat-
ter properties. Flow plots are representative of 
three independent experiments for all but the 
leukemic cells (n = 2). (C) Semiquantitative 
PCR of CD79a, Blnk, and Gapdh. Serial dilu-
tions were done at 1:5. This figure is represen-
tative of three independent experiments 
representing at least one mouse per experi-
ment. Molecular weights are indicated (base 
pairs). Flow cytometric analysis of CD19 ex-
pression on bone marrow cells from Stat5b-CA 
nonleukemic mice, Ebf1+/ nonleukemic mice, 
Stat5b-CA x Ebf1+/ preleukemic mice, and 
lymph nodes cells from Stat5b-CA x Ebf1+/ 
leukemic mice. The controls and gates are as 
in panel B. Flow plots are representative of at 
least three independent experiments.1142 Roles of Ebf1, Pax5, and STAT5 in ALL | Heltemes-Harris et al.
Figure 6.  EBF1 and PAX5 Gene Targets. Microarray analysis of leukemia samples from progenitor B cells from C57BL/6 (LMC) mice (n = 5), Stat5b-CA 
nonleukemic mice (n = 4), and Stat5b-CA x Ebf1+/ mice (n = 5). Cluster analysis was performed using gene lists from previously published tables of PAX5 
or EBF1 gene targets. The heatmap on the left represents all of the genes, regardless of significance, and the enlarged region contains the genes that were 
significant by ANOVA analyses (P < 0.01) and displayed a twofold difference in expression from LMC cells (n = 5). The analysis was performed as described 
in the Materials and methods.JEM Vol. 208, No. 6  1143
Article
The role of STAT5 activation in leukemia has been some-
what controversial. Initial studies by Danial et al. (1995) 
demonstrated that v-Abl induced JAK/STAT signaling in 
pre–B cell lines. Subsequent work with a rather limited number 
of patient samples found elevated STAT5 activation in both 
CML (Chai et al., 1997) and ALL (Weber-Nordt et al., 1996). 
However, studies with STAT5 hypomorphic mice argued 
that this may not be important for transformation as progeni-
tor B cells from such animals were still susceptible to transfor-
mation by Bcr-Abl–expressing retroviruses (Sexl et al., 2000). 
In contrast, we previously demonstrated that mice expressing 
a constitutively active form of STAT5 develop ALL, albeit 
with low penetrance (Burchill et al., 2003; Nakayama et al., 
2009). More recent data using complete STAT5-null mice 
has demonstrated that STAT5 is required for transformation 
by Bcr-Abl–expressing retroviruses (Hoelbl et al., 2006, 2010). 
Supporting these previous findings in mouse models of leu-
kemia, our data examining 129 patients with ALL confirm 
that STAT5 activation occurs in a substantial fraction of ALL 
cases. The BCR-ABL+ subset of ALL exhibited the highest 
degree of STAT5 activation, although other ALL subsets also 
exhibited samples with high levels of STAT5 activation. Most 
importantly, we found that STAT5 activation levels before 
treatment with imatinib (which blocks BCR-ABL–dependent 
STAT5 activation) predicted subsequent outcome with high 
STAT5 activation correlating with poor outcome. This result 
suggests that in patients with lower levels of phospho-STAT5, 
STAT5 activation is driven entirely by BCR-ABL. How-
ever, in patients with higher levels of phospho-STAT5, other 
mechanisms must contribute to STAT5 activation. What these 
mechanisms are remain unclear. One potential mechanism 
we explored is whether haploinsufficiency for either Ebf1 or 
Pax5 resulted in increased STAT5 phosphorylation. How-
ever, we observed no difference in the level of STAT5 phos-
phorylation in progenitor B cells isolated directly from WT, 
Ebf1+/, and Pax5+/ mice (P = 0.75, analysis of variance 
[ANOVA]; unpublished data). It remains possible that com-
pound haploinsufficiency for Ebf1 and Pax5 is required to see 
such an effect; alternatively, other mechanisms may account 
for the differences in STAT5 activation observed in BCR-
ABL patients. Thus, identifying these other mechanisms by 
which STAT5 can be activated in ALL should prove valuable 
for developing more effective therapies, especially for refrac-
tory forms of ALL such as BCR-ABL+ ALL or the recently 
described BCR-ABL–like form of ALL (Den Boer et al., 
2009), both of which have a poor prognosis.
There are several ways in which STAT5 could be acti-
vated in leukemia. First, it is clear that fusion proteins such as 
BCR-ABL can directly phosphorylate, and hence activate, 
STAT5 (Carlesso et al., 1996; Ilaria and Van Etten, 1996). 
Alternatively, as shown in our model, direct mutation of 
STAT5 can promote constitutive STAT5 activation, al-
though it remains unknown how often that actually occurs in 
patients with ALL. In contrast, recent studies have shown 
that activating mutations in the upstream Jak kinases are fre-
quently observed in ALL, particularly refractory subsets of 
subset of EBF1 and PAX5 repressed genes were derepressed. 
This list of gene targets includes several potential oncogenes 
such as Bcl2, Lck, Lmo2, and Vav3 (Marth et al., 1985, 1988; 
Voronova and Sefton, 1986; Boehm et al., 1991; Royer- 
Pokora et al., 1991; Movilla and Bustelo, 1999; Frenzel et al., 
2009; Hirose et al., 2010; Table S3). We confirmed derepres-
sion of several target genes including Bcl2, Tnfsf11, and Itgal 
by RT-PCR and/or flow cytometry (Fig. S5, A and B).   
c-Myc was not included in this initial analysis, as the datasets 
we used did not include it because of ambiguity of whether 
c-Myc is directly repressed by PAX5 or is an indirect PAX5 
target. Regardless of the exact mechanism by which PAX5 
represses c-Myc expression in wild-type progenitor B cells, it 
is clear that c-Myc is strongly derepressed (>11-fold increase 
in expression) in Stat5b-CA x Ebf1+/ leukemias (Table S2). 
The most strongly derepressed of all genes in our analysis   
is Tnfsf11 (44-fold increase in expression), which encodes 
RANKL, a factor known to promote progenitor B cell pro-
liferation (Kong et al., 1999). Both EBF1 and PAX5 repress 
expression of Tnfsf11 (Delogu et al., 2006; Pongubala et al., 
2008; Pridans et al., 2008; Treiber et al., 2010). This prompted 
us to ask whether the list of significantly derepressed genes in   
our leukemias was enriched in genes regulated by both EBF1 
and PAX5. Recent work by Treiber et al. (2010) have found 
that 30 out of 120 PAX5-repressed genes (25%) also ex-
hibit binding of EBF1, suggesting that EBF1 contributes to 
their regulation, either via direct effects on transcription or 
by altering the chromatin configuration of the gene locus. 
When we examined the list of 30 significantly derepressed 
PAX5 target genes in Stat5b-CA x Ebf1+/ leukemias we 
found that 15 of these genes (50%) had been reported to bind 
to EBF1 as well (Table S3). Thus, there is a significant en-
richment in the percentage of PAX5 repressed genes that are 
derepressed in Sta5b-CA x Ebf1+/ leukemias relative to the 
entire dataset of known PAX5-repressed genes (P = 0.006; 2). 
Collectively, our results demonstrate that reduced expres-
sion of Ebf1 and Pax5 correlates with derepression of a sig-
nificant set of EBF1- and PAX5-repressed genes including 
several well-characterized oncogenes such as Bcl2 and c-Myc.
DISCUSSION
Previous studies have demonstrated that a substantial percent-
age of patients with ALL exhibit loss-of-function mutations in 
a set of genes governing B cell development, including Ebf1 
and Pax5 (Mullighan et al., 2007). However, whether these 
mutations actually play an important role in driving the devel-
opment of ALL, and if so what factors they cooperate with to 
do so, has not been determined. Using our newly described 
mouse model of leukemia we demonstrate that haploinsuffi-
ciency of either Ebf1 or Pax5 plays a critical role in initiating 
ALL. Specifically, we demonstrate that loss of one allele of Ebf1 
or Pax5, in combination with STAT5 activation, is sufficient to 
rapidly initiate B cell leukemia with complete penetrance. Thus, 
although other genetic changes likely occur in these leukemias, 
alterations in just the STAT5 and EBF1–PAX5 pathways are 
sufficient to ensure the subsequent development of leukemia.1144 Roles of Ebf1, Pax5, and STAT5 in ALL | Heltemes-Harris et al.
B cells (Table S2). A potential explanation for this observa-
tion is that both Bcl2 and c-Myc are repressed by PAX5   
(as well as EBF1 in the case of Bcl2; Delogu et al., 2006; 
Pongubala et al., 2008). We find here that reduced expres-
sion of Ebf1 and Pax5 enhances the expression Bcl2 and c-Myc, 
suggesting cooperativity between STAT5 activation and loss 
of EBF1 and PAX5 expression in turning on genes that may 
help promote leukemia.
Similarly, Tnfsf11, which is the most highly derepressed 
gene in our leukemias, is a gene that has previously been re-
ported to be repressed by both EBF1 and Pax5 (Delogu et al., 
2006; Pongubala et al., 2008). Although STAT5 has not been 
reported to affect Tnfsf11 expression in lymphocytes, it clearly 
does so in other cell types such as in the developing mam-
mary gland (Srivastava et al., 2003). Once again, despite doc-
umented binding sites for STAT5 in the Tnfsf11 promoter 
(Srivastava et al., 2003), we found that STAT5 activation does 
not induce Tnfsf11 in developing progenitor B cells by itself. 
These findings suggest that cooperation between the positive 
effects of STAT5 activation combined with the loss of repres-
sion mediated by reduced EBF1 and PAX5 function lead to 
high levels of Tnfsf11 expression. Tnfsf11, which encodes 
RANKL, is particularly interesting in the context of transfor-
mation, as it has been previously shown to act as a growth 
factor for developing B cells. Thus, antagonists of RANKL 
may be beneficial in limiting proliferation of ALL cells.
Using microarray analysis and previously published lists   
of EBF1 and PAX5 gene targets, we identified modified ex-
pression of several known tumor suppressor genes and onco-
genes. Interestingly, several of these genes have been identified 
in human B-ALL. One of these genes, BTG1 is commonly 
mutated in human ALL, resulting in loss of expression (Kuiper 
et al., 2007; Mullighan et al., 2007). In one study, loss of BTG1 
expression was linked to leukemias with the TEL-AML1 
translocation, a common form of pediatric ALL. This study 
showed that enforced expression of BTG1 could slow the 
growth of Reh, a TEL-AML1 cell line. This suggested that 
loss of expression of BTG1 enhances cell growth. (Tsuzuki   
et al., 2007). Further, recent data from van Galen et al. (2010) 
demonstrated that loss of BTG1 resulted in resistance of leuke-
mia to glucocorticoid therapy. Another of the genes identi-
fied, LMO2, has been implicated in both B-ALL and T-ALL 
(Royer-Pokora et al., 1991; Cobanoglu et al., 2010; Hirose   
et al., 2010). By reducing expression of LMO2 in an E2A-
HLF ALL cell line, researchers found increased apoptosis, sug-
gesting that increased expression of LMO2 could protect cells 
from cell death (Hirose et al., 2010). Finally, loss of BACH2 
expression, a known tumor suppressor gene, has been linked 
to BCR-ABL+ ALL (Vieira et al., 2001). In this study, loss of 
BACH2 expression was seen in BCR-ABL+ ALL samples, 
suggesting that BCR-ABL can regulate BACH2 expression. 
Together, these data correlating human ALL with genes regu-
lated by EBF1 and PAX5 further illustrate the role these two 
proteins play in the induction of ALL and suggest that further 
examination of genes targeted by EBF1 and PAX5 will be use-
ful in understanding ALL.
ALL (Mullighan et al., 2009b). Interestingly, cases of ALL 
with Jak mutations exhibit overexpression of the TSLPR 
chain. This raises the possibility that endogenous TSLP or 
possibly IL-7, which both activate STAT5, may be important 
for transformation. Consistent with this idea, we demon-
strated that Stat5b-CA x Pax5+/ mice fail to develop leuke-
mia if they lack the IL-7R chain, which is required to 
transduce signals from both TSLP and IL-7. In addition, we 
found increased expression of TSLPR on leukemic cells, but 
not on wild-type or preleukemic control cells. Finally, both 
IL-7 and TSLP act as growth factors for Stat5b-CA x Pax5+/ 
leukemias in vitro. Whether IL-7 or TSLP are needed to in-
crease STAT5 signaling to higher levels than that generated 
by our relatively weak constitutively active STAT5b trans-
gene or to activate other IL-7R–dependent signaling path-
ways remains to be determined. The results from our mouse 
model, combined with data showing a correlation with in-
creased TSLPR expression in some subsets of ALL, suggest 
that mechanisms to inhibit IL-7 and/or TSLP signaling could 
be of value in treating patients with high-risk forms of ALL.
EBF1 and PAX5 potentially promote transformation by 
blocking B cell differentiation. Our finding that Stat5b-CA x 
Rag2/ and Stat5b-CA x MT/ mice also develop ALL 
supports  this  notion.  Importantly,  the  microarray  gene   
signature for Stat5b-CA x Rag2/ leukemia closely resem-
bles that seen in Stat5b-CA x Ebf1+/ mice (unpublished 
data), suggesting a common mechanism of transformation. 
In fact, the entire set of PAX5 and EBF1 target genes de-
scribed in Fig. 6 are similarly de-regulated in Stat5b-CA x 
Rag2/ mice. Consistent with this observation, our micro-
array analysis of Stat5b-CA x Rag2/ leukemias also indi-
cated approximately twofold reductions in Ebf1 and Pax5 
expression (unpublished data). Interestingly, previous stud-
ies have found mutations in the Rag genes in human ALL, 
whereas others have suggested that the pre–BCR acts as a 
tumor suppressor (Mullighan et al., 2007; Trageser et al.,   
2009; Duy et al., 2010). Thus, it is possible that repressing   
pre–BCR expression contributes to the onset of leukemia.   
However, the reduced penetrance and delayed onset of the 
leukemia in Stat5b-CA x Rag2/ mice suggests that EBF1 
and PAX5 play a more fundamental role.
Our data clearly demonstrate that STAT5 activation co-
operates very effectively with partial loss-of-function muta-
tions in Ebf1 or Pax5. STAT5 appears to act in multiple ways 
to  drive  transformation.  First,  nontransformed  progenitor   
B cells from Stat5b-CA mice exhibit a substantial up-regulation 
of Ccnd2, indicating that STAT5 can up-regulate genes involved 
in the cell cycle independent of effects on Ebf1 and Pax5.   
In contrast, several STAT5 target genes are only induced in 
mice with defects in Ebf1 or Pax5. For example, c-Myc and 
Bcl2  have  both  been  reported  to  be  STAT5  target  genes 
(Lord et al., 2000). However, although c-Myc and Bcl2  
levels are significantly increased in Sta5b-CA x Ebf1+/ and 
Stat5b-CA x Pax5+/ leukemias, and likely play an important 
role in transformation, neither of these genes is signifi-
cantly increased in nontransformed Stat5b-CA progenitor JEM Vol. 208, No. 6  1145
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exhibit reduced Ebf1 expression, as that would have given 
rise to a clear defect in pre–B cell differentiation. Therefore, 
we favor a model in which an additional mutation in either 
one allele of Ebf1, or one allele of other genes that encode the 
transcription factor network that governs B cell development 
(including Ikzf1, Tcfe2a, Runx1, Pbx1, and Sfpi1), cooperate 
with Pax5 haploinsufficiency to reduce expression of Ebf1 
and Pax5 factors and thereby drive ALL.
Consistent with our mouse model, previous studies have 
also found multiple cases of human ALL with mutations in 
two or more genes that make up this network (Mullighan   
et al., 2007, 2009a). For example, 85% of BCR-ABL leu-
kemias exhibit mutations in one allele of IKAROS; 50% of 
these leukemias also show mutations in PAX5 (Mullighan 
et al., 2009a). Likewise, TEL-AML leukemias, which essen-
tially have one defective copy of RUNX1 (i.e., AML) fre-
quently exhibit mutations in PAX5 as well (Mullighan et al., 
2007). Finally, ALL with E2A-PBX1 fusions essentially have 
one defective TCFE2A allele and one defective PBX1 allele; 
they also frequently exhibit mutations in PAX5 (Mullighan 
et al., 2007). Importantly, in this model, EBF1 and PAX5 do 
not act as classical tumor suppressor genes in which both alleles 
must be lost, but rather function as part of a tumor suppressor 
gene network in which mutations in any two alleles of the 
network is sufficient to destabilize the tumor suppressor func-
tion of the entire network. Such a model could explain the 
relatively high frequency of mutations in genes that make up 
this network (EBF1, PAX5, IKZF1, TCFE2A, etc.) as trans-
formation would not require mutations in both alleles of any 
one of these genes, but rather mutations in any two alleles of 
any of those genes (for example, in one allele of PAX5 and 
one allele of EBF1). Thus, strategies aimed at enhancing 
the function of this gene network might be efficacious in 
treating B-ALL.
MATERIALS AND METHODS
Mice and cell line. All mice have been previously described (Shinkai et al., 
1992; Urbánek et al., 1994; Lin and Grosschedl, 1995a; Fang et al., 1998; 
Burchill et al., 2003), and the University of Minnesota IACUC approved   
all animal experiments. Tumors were identified by visual examination and 
palpation; mice were euthanized upon tumor identification. Spleen, lymph 
nodes, bone marrow, and peripheral blood were isolated from tumor-bearing 
mice and used for further experiments. Cells were either used directly upon 
isolation or purified using magnetic bead separation for CD19 and B220 
(Miltenyi Biotech).
Kaplan-Meier survival curves were created using Prism software (V5; 
GraphPad Software). Survival of Stat5b-CA x Rag2/, Stat5b-CA x Ebf1+/, 
and Stat5b-CA x Pax5+/ was compared with Stat5b-CA–negative littermate 
controls; all mice were monitored for at least 1 yr or until death. Deaths were 
indicative of tumor development.
For transfer, recipient mice (either C57BL/6 or Rag2/ x Il2rg/) 
were injected with the indicated number of cells i.p., i.v., or via both routes 
of injection.
The ALL cell line (SP1) was created by culturing cells isolated from the 
lymph nodes of a Stat5b-CA x Pax5+/ mouse with leukemia in Opti-MEM 
medium (Invitrogen) supplemented with 4% FBS, 50 µM 2-mercaptoetha-
nol,  2  mM  l-glutamine,  5  I.U.  penicillin,  50  µg/ml  streptomycin,  and   
10 ng/ml IL-7 (PeproTech). Other cytokines tested were GM-CSF, SCF, 
FLT3L, TSLP, G-CSF, and WEHI supernatant (IL-3). All cytokines were 
A key question is what accounts for the altered expression 
of certain EBF1 and PAX5 target genes in Stat5b-CA x Ebf1+/ 
and Stat5b-CA x Pax5+/ leukemias. Our data clearly dem-
onstrate that both Ebf1 and Pax5 continue to be expressed in 
these leukemias. Moreover, the vast majority of EBF1 and 
PAX5 target genes continue to be expressed at wild-type   
levels, suggesting that additional mutations in the remaining 
Ebf1 or Pax5 allele do not account for this effect. The obser-
vation that both Ebf1 and Pax5 levels are reduced in Stat5b-CA x 
Ebf1+/ and Stat5b-CA x Pax5+/ leukemias suggests that   
the target genes that are affected may be those that require 
inputs from both EBF1 and PAX5 for either maximal induc-
tion or repression. Consistent with this hypothesis, over   
two-thirds of Pax5-induced genes were shown by chromatin 
immunoprecipitation assays to be potential EBF1 targets 
(Treiber et al., 2010); many of those genes have been inde-
pendently confirmed to be regulated by EBF1 (Treiber et al., 
2010).  The  case  for  this  is  even  stronger  with  regard  to 
PAX5-repressed genes. The overlap with EBF1 binding is 
much lower for the majority of PAX5-repressed target genes 
identified by previous studies, as only 25% also have validated 
EBF1 binding sites (Treiber et al., 2010). In contrast, in 
Stat5b-CA x Ebf1+/ leukemia cells, 50% of the derepressed 
PAX5 target genes also have validated EBF1 binding sites. 
Thus, there is a clear enrichment in the set of derepressed 
genes in our leukemias that are likely to be regulated by both 
EBF1 and PAX5.
It is still unclear why both Ebf1 and Pax5 levels are re-
duced in Stat5b-CA x Ebf1+/ and Stat5b-CA x Pax5+/ leu-
kemias. This is an important question, as considerable effort 
was spent in the initial publications describing the mutations 
in PAX5 to determine whether both alleles were affected or 
whether  the  PAX5  mutant  encoded  a  dominant-negative 
form of PAX5 that would inhibit function of the remaining 
wild-type allele (Mullighan et al., 2007). The conclusion 
from those studies was that homozygous mutations in PAX5 
(or EBF1) were quite rare, although it was possible that in 
some cases the one mutant PAX5 allele might exhibit a dom-
inant-negative effect. Importantly, our data demonstrate that 
haploinsufficiency of Pax5 is sufficient to drive ALL without 
invoking a dominant negative effect. Because this effect is 
likely caused by reduction of both Pax5 and Ebf1 expression 
acting on key targets (such as Bcl2 and Tnfsf11), it is impor-
tant to understand what accounts for reduced expression of 
both Ebf1 and Pax5. One potential explanation is that in 
Stat5b-CA x Ebf1+/ mice, the reduction in Ebf1 expression 
is sufficient to reduce Pax5 expression as well. This would be 
consistent with the modest defect observed in B cell develop-
ment in Ebf1+/ mice (O’Riordan and Grosschedl, 1999). 
However,  when  we  directly  monitored  PAX5  expression 
levels in Ebf1+/ and Stat5b-CA x Ebf1+/ preleukemic mice, 
we did not observe reduced PAX5 levels. Moreover, this ex-
planation fails to account for the reduced expression of Ebf1 
and Pax5 in Stat5b-CA x Pax5+/ leukemias. Specifically, 
Pax5+/ mice have not been reported to exhibit any haplo-
insufficient effect (Nutt et al., 1997), and therefore cannot 1146 Roles of Ebf1, Pax5, and STAT5 in ALL | Heltemes-Harris et al.
Euclidean  distance  metric,  and  Centroid  Linkage  rule.  Sample  Sizes: 
C57BL/6 pre–B = 5; Stat5b-CA pre–B = 4; Stat5b-CA x Ebf1+/ = 5; 
and Stat5b-CA x Rag2/ = 4. Gene array data are accessible through GEO 
accession no. GSE25645.
Reverse phase protein assays (phospho-STAT5). This study used 129 
samples collected from the blood and/or bone marrow of ALL patients. The 
sample information is described in Table S1. Samples were collected for the 
Leukemia Sample Bank at the University of Texas M.D. Anderson Cancer 
Center between 1992 and 2007. The BCR-ABL+, tyrosine kinase inhibitor–
treated samples were from October 2001 through May 2007. These sam-
ples were collected on institutional review board (IRB)–approved protocol 
Lab01-473, and consent was obtained in accordance with the Declaration of 
Helsinki. Samples were analyzed under an IRB-approved laboratory proto-
col (Lab05-0654). These samples were analyzed using reverse phase protein 
arrays, as previously described (Kornblau et al., 2009).
Online  supplemental  material.  Fig.  S1  shows  that  increased  STAT5 
activation  in  adult  human  ALL  patients  correlate  with  poor  prognosis.   
Fig. S2 includes the rest of the phenotypic analysis of Stat5b-CA x Rag2/ 
leukemic cells. Fig. S3 shows that the leukemic cells are proliferating at a rate 
similar to littermate control progenitor B cells. Fig. S4 shows that a leuke-
mic cell line produced from a Stat5b-CA x Pax5+/ mouse requires either 
IL-7 or TSLP for growth and that leukemic cells express increased levels of 
TSLPR as compared with nonleukemic mice. Fig. S5 shows increased ex-
pression of RANKL, CD11a, and BCL2 on leukemic cells as compared with 
nonleukemic cells. Table S1 contains demographic data for human patient 
samples. Table S2 provides a list of significant genes (P < 0.01 and FC ≥ 2) 
from microarray analysis. Table S3 contains lists of genes generated from 
our microarray analysis and comparison with EBF1- and PAX5-regulated 
genes. Both activated and repressed gene targets of EBF1 and PAX5 that 
were significant (P < 0.01) and displayed a twofold change in expression 
were included. Online supplemental material is available at http://www 
.jem.org/cgi/content/full/jem.20101947/DC1.
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